ライフサイエンスコーパス: active surveillance

1 and in 127 asymptomatic persons in Thailand (active surveillance).

2 uce the need for repeated biopsies (e.g., in active surveillance).

3 t could be managed using watchful waiting or active surveillance).

4 Utilization of active surveillance.

5 fixed power of 150 mW/cm for 22 min 15 s) or active surveillance.

6 ted photodynamic therapy and 207 patients to active surveillance.

7 implications for targeted vector control and active surveillance.

8 cancers who are being encouraged to consider active surveillance.

9 s of non-high-grade DCIS that would preclude active surveillance.

10 tatectomy, 598 (23.5%) EBRT, and 429 (16.8%) active surveillance.

11 rnal beam radiotherapy, and brachytherapy vs active surveillance.

12 monitored via prospective, population-based active surveillance.

13 ined surgery, and who subsequently underwent active surveillance.

14 ient management, particularly with regard to active surveillance.

15 xternal beam radiotherapy, brachytherapy, or active surveillance.

16 external beam radiation therapy (EBRT), and active surveillance.

17 diarrhea and systematically enrolled through active surveillance.

18 on 3 + 4 = 7) prostate cancer may be offered active surveillance.

19 of these patients could benefit from initial active surveillance.

20 s with metastatic renal-cell carcinoma under active surveillance.

21 elopment of an adverse drug reaction through active surveillance.

22 using MRI in the routine follow-up of men on active surveillance.

23 ance biopsies, and may enhance acceptance of active surveillance.

24 s infection in the ICU, without the need for active surveillance.

25 women with CIN2 in a 2-year cohort study of active surveillance.

26 Error rates were measured through active surveillance.

27 y, especially among men who are eligible for active surveillance.

28 and adverse events were ascertained through active surveillance.

29 This was a prospective, population-based, active surveillance.

30 those with low-risk cancer on or considering active surveillance.

31 potentially aggressive tumors unsuitable for active surveillance.

32 grade disease feel more comfortable choosing active surveillance.

33 to determine physician acceptance and use of active surveillance.

34 eview will examine the role of MRI in men on active surveillance.

35 sk prostate cancer and had chosen to undergo active surveillance.

36 001, and December 31, 2015, and managed with active surveillance.

37 15.2 [95% CI, -18.8 to -11.5]) compared with active surveillance.

38 ve techniques, or with watchful waiting with active surveillance.

39 rigger additional imaging and treatment over active surveillance.

40 6 to -2.4]) function at 1 year compared with active surveillance.

41 l tool for detecting tumor recurrence during active surveillance.

42 women with CIN2 in a 2-year cohort study of active surveillance.

43 cer Center (MSK), with a focus on evaluating active surveillance.

44 T (-18.0 points; 95% CI, -20.5 to -15.4) and active surveillance (-12.7 points; 95% CI, -16.0 to -9.3

45 were treated with radiotherapy alone (46%), active surveillance (23%), chemotherapy (16%), combined

46 Only 10 patients managed with active surveillance (27%) eventually required treatment,

47 Of 1141 enrolled men, 314 pursued active surveillance (27.5%), 469 radical prostatectomy (

48 that is, a majority of major changes toward active surveillance (47%) for unknown disease site (103/

49 with better urinary irritative symptoms than active surveillance (5.2 points; 95% CI, 3.2 to 7.2).

50 5% CI, 18.7%-19.5%]) and watchful waiting or active surveillance (9.6% [95% CI, 9.3%-9.9%]).

51 ith early-stage prostate cancer managed with active surveillance, a behavioral intervention that incr

52 At the time of randomization to active surveillance, a significant proportion of patient

53 s, as shown even in recent studies promoting active surveillance; a low recurrence rate of 1-5%; and

54 and urinary incontinence than either EBRT or active surveillance after 3 years and was associated wit

55 In a prospective, population-based, active surveillance, all OM episodes submitted for middl

56 , and the men in the control group underwent active surveillance alone.

57 RO colonization, and infection by leveraging active surveillance and antibiotic treatment data for 23

58 n and infections were not impacted by use of active surveillance and Contact Precautions in LTCF in t

59 d infections were not impacted by the use of active surveillance and contact precautions in LTCFs in

60 area long-term acute-care hospitals included active surveillance and contact precautions.

61 s bacteremia in the ICU without the need for active surveillance and decontamination.

62 ontrolled (i.e., case-crossover) designs for active surveillance and evaluate the ability of the case

63 tcomes were compared between management with active surveillance and other strategies.

64 cer plays a substantial role in adherence to active surveillance and outcomes of men with the disease

65 r is emerging as a management option between active surveillance and radical treatments.

66 d drug-related adverse events and encourages active surveillance and reporting by all physicians.

67 er million) were bacterially contaminated by active surveillance and resulted in 5 STRs occurring 9 t

68 Active surveillance and surge testing were used to detec

69 The lessons learned from active surveillance and their implications include the n

70 prostate cancer , 61.5% (eight of 13) under active surveillance, and 72.0% (18 of 25) in whom recurr

71 y is the highest expenditure associated with active surveillance, and increasing the frequency of pro

72 with PCa prostate cancer who were undergoing active surveillance, and men with treated PCa prostate c

73 statectomy, 12% choosing watchful waiting or active surveillance, and only 3% undergoing radiotherapy

74 invasive cancer, evaluation of a strategy of active surveillance, and testing of decision-making tool

75 patients with cCR were identified: 31 in the active surveillance- and 67 in the immediate surgery gro

76 ancer for determining which men should go on active surveillance; and third, to integrate companion d

77 ly works for applying urinary biomarkers for active surveillance are underway.

78 Active surveillance (AS) for testicular nonseminomatous

79 ients with prostate cancer (PCa) for initial active surveillance (AS) has been questioned on the basi

80 Active surveillance (AS) is increasingly accepted for ma

81 nal plasmas from a prospective cohort of 491 active surveillance (AS) participants indicates prominen

82 Active surveillance (AS), per the National Comprehensive

83 y, or radical prostatectomy) or observation (active surveillance [AS] or watchful waiting [WW]).

84 It is also of use in following up men on active surveillance, as a way to detect change in tumour

85 Compared with active surveillance at 3 months, worsened urinary incont

86 r case-control observational study involving active surveillance at 6 US pediatric medical institutio

87 nction changes not clinically different from active surveillance at any time point through 5 years.

88 ere compared between each treatment group vs active surveillance at each time point.

89 Best practice for active surveillance at the time of study design was foll

90 cussion of management alternatives, he chose active surveillance, but 4 months later a scheduled surv

91 We mimicked active surveillance by conducting sequential analyses af

92 dysfunction often precedes symptoms, needing active surveillance by echocardiography to determine the

93 Multiple studies suggest that MRI early in active surveillance can identify men whose prostate canc

94 ); advanced infection control practices (ie, active surveillance, chlorhexidine bathing, decolonizati

95 as a predictor of outcomes in a multicenter active surveillance cohort.

96 immediate treatment and updates of multiple active surveillance cohorts for men with early-stage pro

97 In reported active surveillance cohorts, prostate cancer death and m

98 cs of managing low-risk prostate cancer with active surveillance compared with other standard therapi

99 tion of the intervention group was receiving active surveillance, compared with the usual care group

100 Forty-nine men on active surveillance completed a 3-arm parallel randomize

101 ed gene expression in the prostate of men on active surveillance, consistent with a reduction in the

102 Active surveillance culture for extended-spectrum beta-l

103 mponents included contact precautions (90%), active surveillance cultures (80%), monitoring, audit an

104 ion of intestinal carriage of ESBL-E through active surveillance cultures (ASC) and the implementatio

105 acteriaceae digestive colonization by weekly active surveillance cultures could reliably exclude the

106 ntroduction of chikungunya in 2015, by using active surveillance data to correct reported dengue case

107 ndividual-level administrative data sets and active surveillance data were joined to estimate influen

108 Combining active surveillance data with routine dengue reports imp

109 Using active surveillance data, we evaluated geographic and te

110 andomizing women with non-high-grade DCIS to active surveillance, defined as imaging surveillance wit

111 Active surveillance demonstrated the considerable burden

112 BRCA2 was recommended for active surveillance discussions.

113 Here, we describe active surveillance efforts in live poultry markets in V

114 Parasitemia was identified by active surveillance every 1-3 months using microscopy an

115 h NS, and no comorbidities, MRI guidance for active surveillance extended life expectancy (eg, 2.60 y

116 to whole gland radiation or surgery or when active surveillance 'fails' (the patient transitions fro

117 admissions specific to rotavirus captured by active surveillance fell by 61-70%.

118 Through nationwide active surveillance for AIVs, 59 H5 LPAIVs were isolated

119 Active surveillance for bloodstream infections has been

120 n in a previously CRE-free region, including active surveillance for CRE carriers and enhanced isolat

121 Active surveillance for CSI testis cancer leads to excel

122 We conducted weekly, active surveillance for diarrhea in 19 villages in Ecuad

123 d serve as a benchmark to compare the use of active surveillance for favorable-risk disease around th

124 Active surveillance for favorable-risk prostate cancer i

125 on comorbidity index of 1 or more, biopsy or active surveillance for growth extended life expectancy

126 depending on risk factors for worsening CKD; active surveillance for growth; and active surveillance

127 Active surveillance for ILI was conducted for approximat

128 infection, detected through population-based active surveillance for influenza in Bangladesh, to asse

129 Active surveillance for influenza-like illness (ILI) was

130 Active surveillance for influenza-like illnesses continu

131 Use of active surveillance for intermediate-risk disease remain

132 nationwide, population-based study on use of active surveillance for localized prostate cancer in Swe

133 Changes include active surveillance for low-risk lesions and a watchful

134 Active surveillance for LRTI was performed for the first

135 One hundred Kenyan infants underwent active surveillance for malaria from birth to 10 months

136 l therapy was developed as an alternative to active surveillance for men with low-risk disease and a

137 ive treatment and use of watchful waiting or active surveillance for men with prostate cancer.

138 he start of a bundled intervention including active surveillance for MRSA.

139 This was prospective national active surveillance for neonatal HSV disease through the

140 Active surveillance for patients with esophageal cancer

141 Active surveillance for posttreatment adverse events was

142 are few therapeutic interventions for men on active surveillance for prostate cancer to reduce the ri

143 ht into worsening renal function in HCM, and active surveillance for renal function should be conside

144 We performed active surveillance for rotavirus hospitalizations at th

145 ne Surveillance Network (NVSN) has conducted active surveillance for RVA at pediatric hospitals and e

146 Active surveillance for TDR is needed to guide ART usage

147 determined that the recommendations from the Active Surveillance for the Management of Localized Pros

148 ASCO endorsed the Active Surveillance for the Management of Localized Pros

149 The Active Surveillance for the Management of Localized Pros

150 warranted to investigate the feasibility of active surveillance for the management of low-grade DCIS

151 ate cancer, and focal therapy may complement active surveillance for those men wishing to continue a

152 It is not clear whether active surveillance for thyroid cancer is widely used.

153 ne physician-reported use of and barriers to active surveillance for thyroid cancer.

154 ed 4 follow-up examinations (2011-2013) with active surveillance for vital status and hospitalization

155 group compared with 120 (58%) of 207 in the active surveillance group (adjusted hazard ratio 0.34, 9

156 treatment compared with 28 (14%) men in the active surveillance group (adjusted risk ratio 3.67, 95%

157 ndings The Pavlik harness group (n = 55) and active surveillance group (n = 49) were comparable for p

158 The most common serious adverse event in the active surveillance group was myocardial infarction (thr

159 otodynamic therapy group vs one [<1%] in the active surveillance group), acute urinary retention (thr

160 were randomized to either Pavlik harness or active surveillance group.

161 roup and 60.0 degrees +/- 5.6 degrees in the active surveillance group.

162 32) in the no prior PCa prostate cancer and active surveillance groups.

163 Patients managed with active surveillance had slightly shorter PFS than those

164 Active surveillance has become the dominant management f

165 The safety of active surveillance has been reinforced by recent report

166 d continuously in Bangladesh since 2007, and active surveillance has detected viral evolution driven

167 Active surveillance has emerged as an alternative to imm

168 Single studies with relevance to active surveillance have evaluated microRNAs, circulatin

169 virus epidemiology by use of data from eight active surveillance hospitals.

170 with fewer urinary irritative symptoms than active surveillance; however, no meaningful differences

171 omarkers geared toward patient selection for active surveillance, identification of clinically signif

172 ren aged 2-59 months were identified through active surveillance in 13 sites.

173 68% (351 of 518) with low-risk disease chose active surveillance in 2014.

174 We implemented active surveillance in 297 households in Peru from Octob

175 ing the effect of abduction treatment versus active surveillance in infants of 3 to 4 months of age.

176 These results suggest that the intensity of active surveillance in patients with rectal cancer manag

177 Thus, the evolving paradigm of active surveillance in prostate and thyroid cancers migh

178 sive, community-based interventions, such as active surveillance in select settings, rather than cont

179 ed biopsy approaches for early diagnosis and active surveillance, in addition to focal therapy.

180 ed this treatment with the standard of care, active surveillance, in men with low-risk prostate cance

181 s reported multiple barriers to implementing active surveillance including patient does not want (80.

182 h for small renal masses that have undergone active surveillance (including biopsy-proven cancers) an

183 The use of active surveillance increased in men of all ages from 57

184 rmed ongoing, prospective, population-based, active surveillance initiated at the time of 7- and 13-v

185 Furthermore, decisions regarding active surveillance involve closely monitoring growth ki

186 This prospective, hospital-based, active surveillance involved 130 pediatric wards and mic

187 Active surveillance is a management strategy for early-s

188 Therefore, it is unclear whether active surveillance is a safe option for African America

189 the limitations of a retrospective analysis, active surveillance is a viable initial management strat

190 Active surveillance is an important option to reduce pro

191 Active surveillance is appropriate for most men with low

192 m the United States show that greater use of active surveillance is important for prostate cancer scr

193 Active surveillance is increasingly accepted as a treatm

194 Continued active surveillance is needed to monitor RVA genotypes i

195 that includes antimicrobial stewardship and active surveillance is needed to prevent CRE infections

196 Active surveillance is performed to detect acute dengue

197 ason score </= 6) localized prostate cancer, active surveillance is the recommended disease managemen

198 The aim of active surveillance is to avoid radical treatment and it

199 ed series of growth rates of renal tumors on active surveillance largely consist of tumors without pa

200 Compared with active surveillance, mean sexual dysfunction scores wors

201 recruited from July 2009 to April 2013 using active surveillance methodology.

202 Community-based mapping and active surveillance must accompany the implementation of

203 We conducted monthly active surveillance (n = 254; 2624 person-months) and we

204 Treatment with active surveillance (n = 363), nerve-sparing prostatecto

205 from 2010-2016 for all 10 Foodborne Disease Active Surveillance Network (FoodNet) sites, having a ca

206 Using a multicenter, active surveillance network from 2 rotavirus seasons (20

207 An active surveillance network was set up to analyze the im

208 ce Monitoring System, and Foodborne Diseases Active Surveillance Network.

209 Monitoring System and the Foodborne Diseases Active Surveillance Network.

210 A strategy of prospective, active surveillance of a clinical registry rapidly ident

211 We evaluated a strategy of prospective, active surveillance of a national clinical registry to m

212 Active surveillance of avian influenza viruses in Bangla

213 Prospective, active surveillance of clinical registries may provide e

214 Population- and laboratory-based active surveillance of CRE conducted among individuals l

215 When selecting patients for active surveillance of DCIS, factors other than tumor bi

216 We used data from active surveillance of diarrheal disease prevalence gath

217 (via examinations, annual phone interviews, active surveillance of discharges from local hospitals,

218 Studies have shown that active surveillance of high-risk patients for VRE coloni

219 We conducted population-based, prospective, active surveillance of iGAS infections throughout the st

220 large-scale seroprevalence studies, enabling active surveillance of infection on a population level.

221 Staphylococcus aureus (MRSA) prevalence via active surveillance of inpatient populations.

222 derived from a population-based, nationwide active surveillance of IPD since 2009.

223 (i.e., using within-person comparisons) for active surveillance of newly marketed drugs.

224 incomplete long-term outcomes ascertainment, active surveillance of the ICD Registry suggests that th

225 timal therapy if it will benefit them and/or active surveillance or best supportive care if it will n

226 , particularly when considering patients for active surveillance or focal therapy.

227 Patients undergoing active surveillance or immediate surgery had a 3-year OS

228 Patients undergoing active surveillance or immediate surgery had a comparabl

229 , OS and PFS in patients with cCR undergoing active surveillance or immediate surgery were not signif

230 adjuvant chemoradiotherapy (nCRT) undergoing active surveillance or immediate surgery.

231 nfavorable tumor pathology in the setting of active surveillance, or in clinical contexts that are in

232 o identify asymptomatic parasitemia and used active surveillance over 11325 child-years of follow-up

233 er, three of four studies come from the same active surveillance patient cohort.

234 Active surveillance patients were enrolled.

235 Europe and the United States have championed active surveillance per the "search and destroy" model.

236 and adult populations using 2 multiregional active surveillance platforms.

237 epeat prostate biopsy strategies, as well as active surveillance, potentially improving sampling effi

238 epartment of Veterans Affairs implemented an active surveillance program for methicillin-resistant St

239 ate cancer prior to commencement of a formal active surveillance programme.

240 Active surveillance programs for MRSA utilize either mol

241 rmacovigilance systems, including conducting active surveillance projects.

242 tate cancer face treatment choices including active surveillance, prostatectomy or radiotherapy.

243 , we report the long-term outcome of a large active surveillance protocol in men with favorable-risk

244 Active surveillance protocols should include prostate-sp

245 uable in informing the development of future active surveillance protocols.

246 provide overviews of existing international active surveillance protocols.

247 Watchful waiting or active surveillance, radiation therapy, or radical prost

248 In settings with active surveillance, reductions in OM caused by vaccine-

249 Active surveillance remains the standard of care for pat

250 Active surveillance represents a cost-effective strategy

251 Active surveillance requires accurate clinical response

252 Thus, active surveillance should be an essential part of conse

253 Active surveillance should be an initial management opti

254 Active surveillance should be considered in this group o

255 Before an active surveillance strategy could be offered to these p

256 Consequently, the active surveillance strategy for low-risk prostate cance

257 val metastases and might become useful in an active surveillance strategy with serial (18)F-FDG PET/C

258 ociated hospitalization rates (P=.003), with active surveillance studies having pooled rates (11.0; 9

259 ns Hopkins University (JHU); Canary Prostate Active Surveillance Study (PASS); University of Californ

260 We conducted a multicenter, hospital-based, active surveillance study at 27 hospitals in India.

261 n enrolled at 8 sites in the Canary Prostate Active Surveillance Study.

262 ed on the results from a large, prospective, active-surveillance study of gastroenteritis outbreaks i

263 n clinical contexts that are informative for active surveillance, such as men with low-risk prostate

264 Active surveillance suggests patient risk 10- to 40-fold

265 The established active surveillance system at 2 hospitals in the capital

266 In this population- and laboratory-based active surveillance system in 7 states, the incidence of

267 Detailed considerations to an active surveillance system that includes reporting, iden

268 Data was obtained from DC's active surveillance system which were geocoded based on

269 ay potentially play a key role in developing active surveillance, systematic evaluation of simple app

270 Recent data from passive and active surveillance systems in the United States indicat

271 phasizing the need for establishing regional active surveillance systems.

272 e studies (e.g., >25,000 patients) show that active surveillance testing (AST) followed by contact pr

273 oints for Enterobacteriaceae and the lack of active surveillance tests hamper the clinical laboratory

274 Active surveillance (the serial monitoring for disease p

275 from January 1966 through January 2016, with active surveillance through December 2016.

276 Despite most physicians considering active surveillance to be appropriate management, more t

277 The role of MRI in active surveillance to date has been in assessing men wi

278 ology and patient characteristics, and offer active surveillance to eligible men with low-risk tumors

279 arding the optimal selection of patients for active surveillance, using more-specific evidence-based

280 The majority (76%) believed that active surveillance was an appropriate management option

281 haracteristics of physicians who stated that active surveillance was appropriate management, but did

282 eatment with radical prostatectomy, EBRT, or active surveillance was ascertained within 1 year of dia

283 ained from children at 2-week intervals, and active surveillance was conducted for respiratory illnes

284 Active surveillance was defined as no definitive treatme

285 ine in sexual domain scores between EBRT and active surveillance was not clinically significant (-4.3

286 ent association of GPS with AP after initial active surveillance was not statistically significant, a

287 pective, enhanced, national population-based active surveillance was undertaken to determine the inci

288 Active surveillance was underused, and a significant pro

289 ses SEER data to examine US trends in use of active surveillance, watchful waiting, radiotherapy, and

290 isolation, patient and staff cohorting, and active surveillance were issued.

291 ths, mean scores between treatment groups vs active surveillance were not significantly different in

292 and method of relapse detection observed on active surveillance were recorded.

293 cted of having prostate cancer or undergoing active surveillance were recruited to a prospective stud

294 ing CKD; active surveillance for growth; and active surveillance when MRI findings are indicative of

295 On the basis of these data, active surveillance with curative intent, in which activ

296 Active surveillance with postponed surgery for recurrent

297 Active surveillance (with visits to health facilities) i

298 d studies comparing an early AVR strategy to active surveillance, with an emphasis on the level of ev

299 seminoma and 1,344 CSI seminoma managed with active surveillance, with the majority treated between 1

300 e receiving cancer-directed therapy or under active surveillance within 6 months of admission.